Cell surface glycosylation has a variety of functions, and its dysregulation in cancer
contributes to impaired signaling, metastasis and the evasion of the immune responses …

Harnessing the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-
L1) axis is pivotal in autoimmunity and cancer immunotherapy. PD-1 receptors on immune …

Most patients with triple negative breast cancer (TNBC) do not respond to anti-PD1/PDL1
immunotherapy, indicating the necessity to explore immune checkpoint targets. B7H3 is a …

Necrotizing enterocolitis (NEC) is a life-threatening disease that predominantly affects very
low birth weight preterm infants. Development of NEC in preterm infants is accompanied by …

Immunotherapy efficacy is limited in melanoma, and combinations of immunotherapies with
other modalities have yielded limited improvements but also adverse events requiring …

Immunotherapy has shown great potential in cancer treatment. However, even with the
intervention of techniques such as immune checkpoint inhibitor therapy, tumors can still …

Antibodies targeting programmed cell death protein 1 (PD-1) or its ligand programmed
death-ligand 1 (PD-L1) are profoundly changing the methods to treat cancers with long-term …

The efficacy of cancer therapies is limited to a great extent by immunosuppressive
mechanisms within the tumor microenvironment (TME). Numerous immune escape …

Melanoma incidence and mortality rates are historically higher for men than women.
Although emerging studies have highlighted tumorigenic roles for the male sex hormone …

Non-clear cell renal cell carcinomas (non-ccRCCs) encompass diverse malignant and
benign tumors. Refinement of differential diagnosis biomarkers, markers for early prognosis …